Biomed 101

Drug Profile

Biomed 101

Alternative Names: Biomed101

Latest Information Update: 04 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Chemoprotectants
  • Mechanism of Action Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Renal cancer

Most Recent Events

  • 01 Oct 2004 BioMedicines is now called Intarcia Therapeutics
  • 07 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the adverse events and Cancer pharmacodynamics sections
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top